NCT03175029View on ClinicalTrials.gov

Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.

PHASE2CompletedINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

September 9, 2017

Primary Completion Date

November 1, 2019

Study Completion Date

March 27, 2020

Conditions
Detrusor UnderactivityOveractive Bladder
Interventions
DRUG

TAC-302

TAC-302 200 mg administered orally twice per day after meals, for 12 weeks.

DRUG

Placebo

Placebo administered orally twice per day after meals, for 12 weeks.

Trial Locations (1)

Unknown

Taiho Pharmaceutical Co., Ltd selected site, Kumamoto

All Listed Sponsors
lead

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

NCT03175029 - Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder. | Biotech Hunter | Biotech Hunter